US Patent Issued to National Research Council of Canada on March 17 for "Antigen-binding agents that specifically bind epidermal growth factor receptor variant III" (Canadian Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,576,133, issued on March 17, was assigned to National Research Council of Canada (Ottawa).

"Antigen-binding agents that specifically bind epidermal growth factor receptor variant III" was invented by Scott McComb (Ottawa), Risini Dhammika Weeratna (Ottawa), Maria Jaramillo (Beaconsfield, Canada), Anne Marcil (Pierrefonds, Canada), Traian Sulea (Kirkland, Canada), Cunle Wu (Montreal) and Darin Bloemberg (Ottawa).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to antigen-binding agents that specifically bind to epidermal growth factor receptor variant III (EGFRvIII). Antigen-binding agents of the present disclosure include an...